Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Allogene ditches enhanced lymphodepletion
The move comes after a death in the Alpha-3 cema-cel study.
Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
Make or break time for Caribou
The company’s matching strategy for CB-010 will soon be put to the test.
